INTRODUCTION The emergence of artificial intelligence (AI) has the potential to revolutionize the pharmaceutical and biotechnology industries improving the efficiency and effectiveness of Medical Science Liaisons (MSLs) and Medical Advisors (MAs) in their daily activities. However, the awareness, understanding, and perceptions of these advanced technologies in these roles … [Read more...]
The MSL Role in The Post-Pandemic Scenario: Lessons Learned and Future Prospects
The COVID19 pandemic has impacted the MSL role and how they interact with KOLs. However, even in this dire situation, 53% of KOLs still consider face-to-face engagement with MSLs very important. Therefore, it is vital to effectively promote this engagement in an adapted way. The MSLs and the KOLs have to adapt to this novel situation, where face-to-face meetings are not always … [Read more...]
Virtual relationships with Key Opinion Leaders (KOLs): Insights from the COVID-19 scenario
The COVID-19 pandemic has represented a 180 degrees’ flip in the way professional relationships are approached between the Pharma industry and HCPs. Consequently, the MSL role has inevitably been impacted by this change of scenario, which has challenged the capacity of self-transformation and adaptation of the ones occupying this position. Especially, the relationships with … [Read more...]
Seasoned MSL Retention
A “seasoned” MSL can be described as one who has changed companies several times due to professional or personal reasons, who has at least 7 years of MSL experience, who is very familiar with the art of being an MSL, who has a solid knowledge of the therapeutic area or disease state they support, and is looking for new challenges. However, the first question we ask ourselves … [Read more...]
Do you think there will be any permanent long-term impact or changes to the MSL profession as a result of the COVID-19 pandemic?
Results are totally divided between those who believe there will be permanent changes and those who do not expect changes, along with those who are not yet sure. The survey results clearly reflect the situation in which our profession is currently immersed. From my point of view, whether we like it or not, the current restrictions are going to have an impact on our day to … [Read more...]
MSL and CRA: A Responsibility Model for the Efficiency of Clinical Research and Clinical Trials
The pharmaceutical industry has been evolving and changing along the years, as has the way in which clinical trials are planned and executed. Clinical Development went from a fully inhouse clinical trials handling model, where each company had its own team of clinical operations to execute those trials, to a completely outsourced model where none of the members of the team were … [Read more...]